
Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma
pharmafile | December 16, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Roche, melanoma, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when combined with Cotellic (cobimetinib) and Zelboraf (vemurafenib), met its primary endpoint in the treatment of previously untreated BRAF V600 mutation-positive advanced melanoma.
While specifics of the findings were not revealed, Roche confirmed that the combo generated a “significant and clinically meaningful” improvement in progression-free survival (PFS) compared to placebo plus Cotellic and Zelboraf.
The company also confirmed that the full details of the findings would be presented at an upcoming medical meeting, and that they will also help form the basis for regulatory submissions with the FDA and EMA.
“By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma,” commented Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche. “We look forward to discussing the results with health authorities around the world.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Five facts about UV exposure and sun safety
1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s …






